OrbusNeich(R) Announces China Approval for COMBO(R) Coronary Stent

Food and Healthcare Press Releases Wednesday September 23, 2020 15:00
HONG KONG--23 Sep--PRNewswire/InfoQuest

OrbusNeich Medical Co. Ltd. has announced that the National Medical Products Administration (NMPA) has granted market approval for the COMBO BIO-ENGINEERED SIROLIMUS ELUTING STENT in China. It is the first dual therapy stent to both accelerate endothelial coverage and control neointimal proliferation through the combination of the proven pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissipation by 90 days.

OrbusNeich's patented endothelial progenitor cell (EPC) capture technology promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

"The market approval of the COMBO Stent in the Republic of China is a strategically important success for the OrbusNeich organization as we further expand into significant territories," said David Chien, OrbusNeich's Chairman, President and CEO. "We expect the approval of a unique product such as the COMBO Stent to allow OrbusNeich to strengthen our presence in China alongside our existing PTCA and PTA portfolio."

The ongoing randomized, multi-center RECOVERY trial [NCT02542007] comparing the COMBO Stent with the polymer-free sirolimus-eluting Nano stent (PF-SES) (Lepu Medical Technology, Beijing, China) in the treatment of patients with de novo native coronary artery lesions provided clinical data supporting the approval. A total of 432 patients were enrolled at 16 centers in China and randomized one-to-one to the treatment with COMBO Stent or the treatment with PF-SES. In this positive trial, the COMBO Stent was found to be non-inferior in the study primary endpoint of 9-month angiographic in-segment late lumen loss compared to the PF-SES, with in-segment LLL of 0.29 ? 0.46 mm and 0.31 ? 044 mm respectively (p = 0.57). At 1-year, clinical outcomes were similar between the groups for target lesion failure (TLF), a composite of cardiac death, target-vessel myocardial infarction, or ischemia-driven target lesion revascularization, and all TLF components. There was no stent thrombosis in either group.

"Since its launch, the COMBO Stent has played an important role in helping patients with coronary artery disease," said Senior Vice President and Chief Commercial Officer, Alain Khair. "The COMBO Stent, with its unique pro-healing properties, is another example of OrbusNeich's commitment to providing innovative best-in-class devices to our physicians and their patients."

About OrbusNeich – Pioneers in life-changing technologies

OrbusNeich is a global pioneer in the provision of life-changing vascular solutions and offers an extensive portfolio of products that set industry benchmarks in vascular intervention. Current products are the COMBO Stent, together with stents and balloons marketed under the names of COMBO Plus, AZULE(R), SCOREFLEX(R), SCOREFLEX(R) NC, SAPPHIRE(R) II PRO, SAPPHIRE(R) 3 and SAPPHIRE(R) II NC, and the TELEPORT(R) microcatheter, as well as products to treat peripheral artery disease: the JADE(R) and SCOREFLEX(R) PTA balloons.

OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Florida, USA; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to physicians in more than 60 countries. For more information, visit www.OrbusNeich.com.

Latest Press Release

Nature's Sensation shares tips of how to drink cranberry juice for being healthy all year long

New Year is a very good start for people to begin something new and make a change in their life, but due to the spread of Covid-19, selfcare seems to be the first priority that should not be ignored. To promote well-being, the best practices surely must...

Prudential Launches New Research that Underscores Critical Role of Technology in Improving Healthcare in Asia

88% of Thai respondents are using digital technologies to manage their personal health. This number is the highest across the ASEAN nations surveyed81% of respondents across Asia say technology has improved their access to health services71% of...

New report from FDI World Dental Federation tackles oral health inequalities and outlines strategies to improve oral healthcare over the next ten years

- Oral conditions such as tooth decay, gum disease, tooth loss and oral cancer are the most widespread noncommunicable diseases worldwide - impacting 3.5 billion people - and have severe and significant health, societal, and economic impacts. - Oral...

Nonin Medical Announces New Full Board of Directors

Nonin Medical announced the appointment of four new members to the company's board of directors. Each of the new directors brings unique industry experience and passion for innovation in the medtech and healthcare sectors. Together, they will provide...

Medical Microinstruments Appoints Healthcare Industry Veteran Mark Toland as Chief Executive Officer

Toland joins Andrew Cleeland (Chairman of the Board, MMI) in developing the field of robotic-assisted microsurgery Medical Microinstruments (MMI) SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery,...

Related Topics